产品说明 应用 SB 204741 has been used as a 5-hydroxytryptamine receptor 2B (Htr2B) antagonist:
- to inhibit Htr2b signaling to test its effect on hepatic stellate cell (HSC) activation in three-month-old adult zebrafish
- to test its effect on the inhibition of fluoxetine effects in depressive-like behavioral studies in mice
- to test its effect in reducing scratching behavior evoked by sertraline in mice
包装 10, 50 mg in glass bottle 生化/生理作用 SB 204741 reduces the synaptic facilitation induced by the low dose of buprenorphine in spinal C-fiber synapses.
5-HT2B serotonin receptor antagonist. 特点和优势 This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here. 法律信息 Sold for research purposes under agreement from GlaxoSmithKline 基本信息 | 经验(实验)分子式 | C14H14N4OS | | 分子量 | 286.35 | | MDL编号 | MFCD00923644 | | PubChem化学物质编号 | 24278321 | | NACRES | NA.77 |
产品性质 | 质量水平 | 100 | | 测定 | >98% (HPLC) | | 形式 | solid | | 颜色 | off-white to tan | | 溶解性 | DMSO: soluble >20 mg/mL | | 创始人 | GlaxoSmithKline | | 储存温度 | 2-8℃ | | SMILES string | Cc1cc(NC(=O)Nc2ccc3n(C)ccc3c2)sn1 | | InChI | 1S/C14H14N4OS/c1-9-7-13(20-17-9)16-14(19)15-11-3-4-12-10(8-11)5-6-18(12)2/h3-8H,1-2H3,(H2,15,16,19) | | InChI key | USFUFHFQWXDVMH-UHFFFAOYSA-N | | Gene Information | human ... DRD2(1813), DRD3(1814), DRD5(1816), HTR1E(3354), HTR2A(3356), HTR2B(3357), HTR2C(3358)
rat ... Adra1a(29412), Gabra2(29706), Htr1a(24473), Htr2b(29581), Htr3a(79246) |
安全信息 | 象形图 |  | | 警示用语： | Warning | | 危险声明 | H315 - H319 - H335 | | 预防措施声明 | P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338 | | 危险分类 | Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 | | 靶器官 | Respiratory system | | 储存分类代码 | 11 - Combustible Solids | | WGK | WGK 3 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable | | 个人防护装备 | dust mask type N95 (US), Eyeshields, Gloves |
|
m.cnreagent.com